Taiho Pharmaceutical Co., Ltd. — China drug registrations and re-registration deadlines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2028-02-23.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20130811 | ———— 替吉奥胶囊 | 2028-08-23 | 2028-02-23 |
| 国药准字HJ20130812 | ———— 替吉奥胶囊 | 2028-08-23 | 2028-02-23 |
| 国药准字HJ20130816 | ———— 替吉奥胶囊 | 2028-08-23 | 2028-02-23 |
| 国药准字HJ20130817 | ———— 替吉奥胶囊 | 2028-08-23 | 2028-02-23 |
| 国药准字HJ20190048 | Trifluridine and Tipiracil Hydrochloride Tablets 曲氟尿苷替匹嘧啶片 | 2029-04-24 | 2028-10-24 |
| 国药准字HJ20190049 | Trifluridine and Tipiracil Hydrochloride Tablets 曲氟尿苷替匹嘧啶片 | 2029-04-24 | 2028-10-24 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.